A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 6,069 shares of ATAI stock, worth $9,771. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,069
Previous 4,998 21.43%
Holding current value
$9,771
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$1.16 - $1.64 $1,242 - $1,756
1,071 Added 21.43%
6,069 $7,000
Q2 2024

Jul 30, 2024

BUY
$1.27 - $2.6 $6,347 - $12,994
4,998 New
4,998 $6,000
Q4 2023

Jan 24, 2024

SELL
$1.04 - $1.55 $8,354 - $12,451
-8,033 Reduced 1.27%
623,677 $879,000
Q3 2023

Oct 26, 2023

BUY
$1.27 - $2.28 $110,996 - $199,269
87,399 Added 16.06%
631,710 $814,000
Q2 2023

Aug 10, 2023

SELL
$1.44 - $2.19 $92,481 - $140,648
-64,223 Reduced 10.55%
544,311 $936,000
Q1 2023

May 04, 2023

BUY
$1.17 - $2.7 $194,121 - $447,973
165,916 Added 37.49%
608,534 $1.1 Million
Q4 2022

Feb 09, 2023

SELL
$2.38 - $3.55 $16,072 - $23,973
-6,753 Reduced 1.5%
442,618 $1.18 Million
Q3 2022

Nov 10, 2022

SELL
$3.14 - $4.87 $28,181 - $43,708
-8,975 Reduced 1.96%
449,371 $1.49 Million
Q2 2022

Jul 26, 2022

BUY
$3.03 - $5.32 $122,739 - $215,502
40,508 Added 9.69%
458,346 $1.67 Million
Q1 2022

May 10, 2022

BUY
$4.66 - $7.66 $464,518 - $763,564
99,682 Added 31.33%
417,838 $2.13 Million
Q4 2021

Feb 08, 2022

BUY
$6.82 - $17.8 $171,141 - $446,673
25,094 Added 8.56%
318,156 $2.43 Million
Q3 2021

Nov 15, 2021

BUY
$13.62 - $19.48 $3.99 Million - $5.71 Million
293,062 New
293,062 $4.33 Million

Others Institutions Holding ATAI

About ATAI Life Sciences N.V.


  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $267M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.